European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps - CureVac (NASDAQ:CVAC)

European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps - CureVac (NASDAQ:CVAC)

CureVac N.V. (NASDAQ:CVAC) on Thursday said the European Patent Office (EPO) confirmed the validity of CureVac’s European patent EP 3 708 668 B1 subject to amendments to specify the scope of protection. The opposition division largely dismissed the opposition originally filed by BioNTech SE (NASDAQ:BNTX) in April 2023, challenging the patent’s validity and maintaining the patent in amended form. Also Read: Deadly Bird Flu Strain Detected In Neva…

European Patent Office rejects BioNTech SE's opposition of April 2023 against the validity of EP 3 708 668 B1 as far as possible and maintains patent in amended form Hearing on the infringement of EP 3 708 668 B1 scheduled for 1 July 2025 before the Regional Court Düsseldorf Confirmation of the validity of the patent in amended form is an important milestone in broad patent dispute in Germany for the assessment of CureVac's groundbreaking mRNA i…